Monte Rosa Therapeutics Shares Rise on Upcoming Clinical Trial Review
Monte Rosa Therapeutics (MRSA) stock climbed 20% in premarket trading after the company announced it will host a conference call Thursday to review clinical results from a recent study.
Story updates
11:00:03 AM UTC
SquawkNews
GLUE - Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk